Table 2.
Median HbA1c levels at baseline and within-person change from baseline to end of follow-up by treatment arm
| Variable | Men | Women | Men and women | |||
|---|---|---|---|---|---|---|
| Placebo (n = 924) |
Atorvastatin (n = 937) |
Placebo (n = 437) |
Atorvastatin (n = 441) |
Placebo (n=1,361) |
Atorvastatin (n =1,378) |
|
| Baseline HbA1c, % | 7.6 (6.8–8.7) | 7.7 (6.8–8.7) | 7.6 (6.9-8.8) | 7.8 (6.9–8.9) | 7.6 (6.8–8.7) | 7.8 (6.8–8.7) |
| Baseline HbA1c, mmol/mol | 59.6 (50.8–71.6) | 60.7 (50.8–71.6) | 59.6 (51.9-72.7) | 61.7 (51.9–73.8) | 59.6 (50.8–71.6) | 61.7 (50.8–71.6) |
| Last follow-up HbA1c, % | 7.8 (7.0–8.7) | 7.9 (7.1–9.0) | 7.8 (7.1-8.9) | 8.0 (7.1–8.9) | 7.8 (7.1–8.8) | 7.9 (7.1–9.0) |
| Last follow-up HbA1c, mmol/mol | 61.7 (53.0–71.6) | 62.8 (54.1–74.9) | 61.7 (54.1-73.8) | 63.9 (54.1–73.8) | 61.7 (54.1–72.7) | 62.8 (54.1–74.9) |
| Unadjusted within-person change in HbA1c, % | 0.2 (−0.5–0.9) | 0.3 (−0.5–1.1) | 0.3 (-0.6-1.1) | 0.2 (−0.6–1.0) | 0.2 (−0.5–1.0) | 0.2 (−0.5–1.1) |
| Unadjusted within-person change in HbA1c, mmol/mol | 2.2 (−5.5–9.8) | 3.3 (−5.5–12.0) | 3.3 (-6.6-12.0) | 2.2 (−6.6–10.9) | 2.2 (−5.5–10.9) | 2.2 (−5.5–12.0) |
Data are median (IQR), unless otherwise stated